In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay

In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay

Show other versions (1)

Introduction: Enterococci have become the third major leading cause of nosocomial bacteraemia, an infection which is significantly associated with the risk of developing infective endocarditis. Linezolid provides high rates of clinical cure and microbiologic success in complicated infections due to...

Full description

Bibliographic Details
Main Authors: Gustavo Enck Sambrano, Thiago Galvão da Silva Paim, Lucas Toniolo da Silva, Pedro Alves d'Azevedo
Format: Article
Language:English
Published: Hospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS) 2014-08-01
Series:Clinical and Biomedical Research
Subjects:
Enterococcus
Anti-Infective Agents
Bacterial Growth
Online Access:http://seer.ufrgs.br/index.php/hcpa/article/view/48369

Similar Items

Similar Items